Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-055754
Filing Date
2025-04-18
Accepted
2025-04-18 08:05:07
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2025_defa14a.htm DEFA14A 22232
2 GRAPHIC img213474020_0.jpg GRAPHIC 3933891
3 GRAPHIC img213474020_1.jpg GRAPHIC 535970
  Complete submission text file 0000950170-25-055754.txt   6177356
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37783 | Film No.: 25849252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)